Nasdaq

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...
Morningstar

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of ...
Nasdaq

TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...
Healio

Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara

Please provide your email address to receive an email when new articles are posted on . Tremfya is the first approved IL-23 inhibitor to offer both IV and fully subcutaneous induction regimens. This ...
Morningstar

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...
Managed Healthcare Executive

New self-injectable biologics promise cost savings and patient convenience

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
Yahoo

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis

Johnson & Johnson (J&J) Innovation Medicine has submitted a request to the US Food and Drug Administration (FDA) to approve a new way of starting treatment with its drug Tremfya (guselkumab) for ...
Daily Local News

New Phase 3 Data Show First-in-Class TREMFYA(R) (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis ...

In addition, results showed 56 percent of TREMFYA q4w patients and 55 percent of TREMFYA q8w patients achieved at least 50 percent improvement in ACR score (utilizing NRI). 2 Among patients who had ...
Monthly Prescribing Reference

Tremfya One-Press Patient-Controlled Injector Approved for Patients With Moderate-to-Severe Plaque Psoriasis

The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults. The Food and Drug ...
manilatimes

TREMFYA (guselkumab) receives positive CHMP opinion for subcutaneous induction regimen in ulcerative colitis, a first for an IL-23 inhibitor

Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and intravenous induction options inulcerative colitis, providing flexibility and simplicity for patients ...
Seeking Alpha

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...